These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 15461620)

  • 21. The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of sixty two patients.
    Noble SI; Hood K; Finlay IG
    Palliat Med; 2007 Sep; 21(6):473-6. PubMed ID: 17846086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging anticoagulants for the treatment of venous thromboembolism.
    Weitz JI
    Thromb Haemost; 2006 Sep; 96(3):274-84. PubMed ID: 16953267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of recurrent idiopathic venous thromboembolism.
    Goldhaber SZ
    Circulation; 2004 Dec; 110(24 Suppl 1):IV20-4. PubMed ID: 15598644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recurrent venous thromboembolism in patients with and without anticoagulation after inferior vena caval filter placement.
    Yale SH; Mazza JJ; Glurich I; Peters T; Mukesh BN
    Int Angiol; 2006 Mar; 25(1):60-6. PubMed ID: 16520726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of thromboembolism with short-term interruption of warfarin therapy.
    Garcia DA; Regan S; Henault LE; Upadhyay A; Baker J; Othman M; Hylek EM
    Arch Intern Med; 2008 Jan; 168(1):63-9. PubMed ID: 18195197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sublingual administration of warfarin: a novel form of delivery.
    Batke-Hastings S; Carman TL
    Vasc Med; 2008; 13(2):123-6. PubMed ID: 18593801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low thromboembolic risk for patients with the Heartmate II left ventricular assist device.
    John R; Kamdar F; Liao K; Colvin-Adams M; Miller L; Joyce L; Boyle A
    J Thorac Cardiovasc Surg; 2008 Nov; 136(5):1318-23. PubMed ID: 19026822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative efficacy and safety of low-intensity warfarin therapy in preventing unprovoked recurrent venous thromboembolism: A systematic review and meta-analysis.
    Jiang R; Shi Y; Zhang R; Pudasain B; Wang L; Zhao QH; Yuan P; Guo J; Zhu CT; Liu JM
    Clin Respir J; 2018 Jul; 12(7):2170-2177. PubMed ID: 29601145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimizing use of current anticoagulants.
    Witt DM
    Hematol Oncol Clin North Am; 2010 Aug; 24(4):717-26, viii. PubMed ID: 20659656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy.
    Sallah S; Husain A; Sigounas V; Wan J; Turturro F; Sigounas G; Nguyen NP
    Clin Cancer Res; 2004 Nov; 10(21):7238-43. PubMed ID: 15534097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Standard-intensity vs low-dose anticoagulation for long-term management of patients with venous thromboembolism.
    Lazo-Langner A; Kovacs MJ
    Clin Adv Hematol Oncol; 2005 Nov; 3(11):877-9. PubMed ID: 16491633
    [No Abstract]   [Full Text] [Related]  

  • 32. Update in the treatment of venous thromboembolism.
    Garcia DA; Spyropoulos AC
    Semin Respir Crit Care Med; 2008 Feb; 29(1):40-6. PubMed ID: 18302085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Optimum duration of anticoagulant treatment after an episode of venous thromboembolism].
    Couturaud F; Kearon C
    Rev Pneumol Clin; 2008 Dec; 64(6):305-15. PubMed ID: 19084210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of pharmacist-managed oral anticoagulation therapy in older veterans.
    Poon IO; Lal L; Brown EN; Braun UK
    J Clin Pharm Ther; 2007 Feb; 32(1):21-9. PubMed ID: 17286786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recurrent thromboembolism in cancer patients: incidence and risk factors.
    Prandoni P; Piccioli A; Pagnan A
    Semin Thromb Hemost; 2003 Dec; 29 Suppl 1():3-8. PubMed ID: 14730471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival.
    Nishioka J; Goodin S
    J Oncol Pharm Pract; 2007 Jun; 13(2):85-97. PubMed ID: 17873108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Warfarin versus low-molecular-weight heparin therapy in cancer patients.
    Zacharski LR; Prandoni P; Monreal M
    Oncologist; 2005 Jan; 10(1):72-9. PubMed ID: 15632254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does antithrombotic therapy improve survival in cancer patients?
    Cunningham MS; Preston RJ; O'Donnell JS
    Blood Rev; 2009 May; 23(3):129-35. PubMed ID: 19046797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deep vein thromboembolism in malignant diseases.
    Zemková M; Meyboom RH; Blazek M; Kotlárová J; Vlcek J; Jebavý L
    Ceska Slov Farm; 2007 Jan; 56(1):5-10. PubMed ID: 17432275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
    Huo MH; Muntz J
    Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.